Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef

被引:28
作者
Allard, Sabine D. [1 ,2 ]
Pletinckx, Katrien [1 ]
Breckpot, Karine [1 ]
Heirman, Carlo [1 ]
Bonehill, Aude [1 ]
Michiels, Annelies [1 ]
van Baalen, Carel A. [3 ]
Gruters, Rob A. [3 ]
Osterhaus, Albert D. M. E. [3 ]
Lacor, Patrick [2 ]
Thielemans, Kris [1 ]
Aerts, Joeri L. [1 ]
机构
[1] Vrije Univ Brussels, Sch Med, Dept Phys & Immunol, Lab Mol & Cellular Therapy, B-1090 Brussels, Belgium
[2] Univ Ziekenhuis St Rafael, Dept Int Med & Infect Dis, AIDS Unit, B-1090 Brussels, Belgium
[3] Erasmus MC, Dept Virol, NL-3015 GD Rotterdam, Netherlands
关键词
early expressed HIV-1 proteins; therapeutic vaccine; dendritic cells;
D O I
10.1016/j.vaccine.2008.04.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The limitations of highly active anti-retroviral therapy (HAART) have necessitated the development of alternative therapeutic strategies. One of the approaches that has gained prominence in recent years is therapeutic vaccination. We decided to assess the capacity of mature dendritic cells, derived from blood monocytes of HIV-1 infected patients, to generate functional T-cell responses. For this purpose, we constructed a chimeric mRNA encoding the proteins Tat, Rev and Nef. The TaReNef encoding information was linked to the HLA class II-targeting sequence of DC-LAMP. Broadly directed HIV-specific CD4(+) and CD8(+) cytotoxic T cells exhibiting a poly-functional cytokine secretion pattern were generated by co-culturing with autologous chimeric mRNA electroporated dendritic cells. Thus, administration of ex vivo generated dendritic cells expressing the early proteins Tat, Rev and Nef might offer a promising approach for therapeutic vaccination in HIV-1 infection. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3735 / 3741
页数:7
相关论文
共 46 条
[1]  
Almeida M, 2005, AIDS, V19, P261
[2]   Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression [J].
Appay, V ;
Hansasuta, P ;
Sutton, J ;
Schrier, RD ;
Wong, JK ;
Furtado, M ;
Havlir, DV ;
Wolinsky, SM ;
McMichael, AJ ;
Richman, DD ;
Rowland-Jones, SL ;
Spinha, CA .
AIDS, 2002, 16 (02) :161-170
[3]   HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function [J].
Appay, V ;
Nixon, DF ;
Donahoe, SM ;
Gillespie, GMA ;
Dong, T ;
King, A ;
Ogg, GS ;
Spiegel, HML ;
Conlon, C ;
Spina, CA ;
Havlir, DV ;
Richman, DD ;
Waters, A ;
Easterbrook, P ;
McMichael, AJ ;
Rowland-Jones, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :63-75
[4]   Opinion -: Therapeutic vaccines against HIV need international partnerships [J].
Autran, B ;
Debré, P ;
Walker, B ;
Katlama, C .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (06) :503-508
[5]   Dendritic cells as therapeutic vaccines against cancer [J].
Banchereau, J ;
Palucka, AK .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306
[6]   HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells [J].
Betts, Michael R. ;
Nason, Martha C. ;
West, Sadie M. ;
De Rosa, Stephen C. ;
Migueles, Stephen A. ;
Abraham, Jonathan ;
Lederman, Michael M. ;
Benito, Jose M. ;
Goepfert, Paul A. ;
Connors, Mark ;
Roederer, Mario ;
Koup, Richard A. .
BLOOD, 2006, 107 (12) :4781-4789
[7]   Presence of HIV-1 gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection [J].
Boaz, MJ ;
Waters, A ;
Murad, S ;
Easterbrook, PJ ;
Vyakarnam, A .
JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6376-6385
[8]   Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy [J].
Bonehill, A ;
Heirman, C ;
Thielemans, K .
JOURNAL OF GENE MEDICINE, 2005, 7 (06) :686-695
[9]   Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules [J].
Bonehill, A ;
Heirman, C ;
Tuyaerts, S ;
Michiels, A ;
Breckpot, K ;
Brasseur, F ;
Zhang, Y ;
van der Bruggen, P ;
Thielemans, K .
JOURNAL OF IMMUNOLOGY, 2004, 172 (11) :6649-6657
[10]   IDENTIFICATION OF AN ARG-GLY-ASP (RGD) CELL-ADHESION SITE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSACTIVATION PROTEIN, TAT [J].
BRAKE, DA ;
DEBOUCK, C ;
BIESECKER, G .
JOURNAL OF CELL BIOLOGY, 1990, 111 (03) :1275-1281